Molecular hydrogen (H₂) therapy is an emerging, low-risk modality that we offer at Regeneris Therapy as a complementary adjunct to our better-evidenced regenerative protocols — not as a primary treatment for any disease. The biology is interesting: H₂ is a small, neutral molecule that diffuses readily into tissues and appears to act as a selective antioxidant against the most damaging reactive oxygen species while leaving physiologically necessary ones intact. The clinical evidence is preliminary; most published studies are small, short, or in animal models, and we treat the human evidence as investigational. We are honest about this. Read on for what molecular hydrogen does (and does not do), how it is delivered, what the current evidence supports, how we integrate it with other therapies, and why our framing is deliberately cautious.
What molecular hydrogen does: selective antioxidant for the most damaging ROS
Reactive oxygen species (ROS) are a normal product of cellular metabolism, and not all of them are bad. Hydrogen peroxide and superoxide play important signaling roles in immune defense, vascular tone regulation, and cellular communication. The problem is a smaller subset of more aggressive ROS — primarily the hydroxyl radical (·OH) and the peroxynitrite anion (ONOO⁻) — which are highly reactive, damage lipids, proteins, and DNA indiscriminately, and accumulate in conditions of chronic inflammation, ischemia-reperfusion injury, and accelerated aging. Conventional antioxidant supplements (high-dose vitamin C, vitamin E) tend to neutralize ROS broadly, which can blunt useful signaling and has produced disappointing results in large clinical trials. Molecular hydrogen appears to be different: laboratory and animal studies suggest it preferentially neutralizes hydroxyl radical and peroxynitrite while leaving the physiologically useful ROS largely intact. The framing matters: we do not present H₂ as a generic 'antioxidant supplement' but as a selective signaling modulator with an interesting mechanistic profile. The human clinical translation of that profile is still being worked out.
